Genzyme seeks to treat adult leukemia Nov 25, 2008
This cancer drug was developed in San Antonio by ILEX Oncology a predecessor company to Genzyme Oncology. ILEX merged with Cambridge, Mass. (San Antonio Business Journal, TX)
TGen spin-off MedTrust Online enables cancer doctors to quickly obtain best-available information Oct 23, 2008
"While MedTrust is our third spin-off company, it is a first in the informatics area for TGen Accelerators, and marks a beginning in the effort to use the vast knowledge generated by TGen scientists for the commercial benefit of doctors and the general public,'' said MaryAnn Guerra, TGen's Chief Business Officer and President of TGen Accelerators. Richard Love, a former TGen Chief Operating Officer and former CEO of ILEX Oncology Inc, praised the advent of MedTrust as a boost to the local... (EurekAlert! -- Business News)
Pharmacyclics, Inc. Announces Board and Management Transitions Sep 12, 2008
Mr. Duggan stated: "Pharmacyclics has an exceptional team of dedicated employees who have worked hard to build a sustainable portfolio of drugs to fight many diseases. I respect and admire this team and look forward to working together with them in the future." Dr. Miller commented: "We have built a significant portfolio of products under my tenure. I am gratified at the support I have received from the stockholders, Board of Directors and employees of the Company over the time that I have... (PR Newswire)
Local software firm teams with Austin consulting group Jul 24, 2008
iNQUATE was founded in July 2005 by Diane Clements husband Ian Clements, John Barnes and Lauren Harper, all employees of the former San Antonio-based Ilex Oncology Inc., now based in Cambridge, Mass. Diane Clements says that the group decided to form the company after realizing they could develop a system to track corporate and employee performance managing human capital and improving corporate DNA much the same way they had developed software with Ilex Oncology tracking physiological... (San Antonio Business Journal, TX)
Cancer drug company OncoVista names new CFO Jan 9, 2008
Prior to that, he was the assistant controller at ILEX Oncology, where he prepared all external public filings. OncoVista's CEO Alexander L. Weis was one of the co-founders of ILEX Oncology, which eventually merged with Cambridge, Mass. (San Antonio Business Journal, TX)
OncoVista hires Porter, LeVay & Rose to manage investor relations Dec 6, 2007
Porter also notes that Weis was a co-founder of ILEX Oncology Inc. in San Antonio, which was subsequently sold to (NASDAQ: GENZ) for more than $1 billion. OncoVista is engaged in the development and commercialization of targeted therapies for the treatment of cancer. (San Antonio Business Journal, TX)
Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results Nov 8, 2007
Recent Events -- Announced agreement to acquire ZEVALIN(R) (ibritumomab tiuxetan), the first FDA-approved radioimmunotherapy, from Biogen Idec; this acquisition, if completed, will return CTI to a select group of only a few biotech companies which market and sell a commercial product -- Announced a potential abbreviated registration path for pixantrone based on the Company's decision to do a full analysis of the EXTEND (PIX301) phase III clinical trial for patients with relapsed, aggressive... (PR Newswire)
Bioenvision shareholders OK Genzyme buy-out Oct 24, 2007
Clofarabine was developed in San Antonio by the former ILEX Oncology Inc., which Genzyme bought in 2004. ILEX was subsequently renamed Genzyme Oncology and continues to have a major presence in San Antonio. (San Antonio Business Journal, TX)
Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI) Sep 24, 2007
He founded two biopharmaceutical companies, Triton Biosciences Inc. and ILEX Oncology, Inc. Love was CEO at both companies, and leading the clinical development teams in the creation of four drugs currently in use -- Betaseron(R), a treatment for multiple sclerosis, two treatments for chronic lymphocytic leukemia, Fludara(R) and CAMPATH(R), and Clolar(R), a treatment for acute leukemias. "We are very excited to have Dick join CTI's board, and look forward to utilizing his industry expertise,"... (PR Newswire)
ImaRx Therapeutics names new chairman Sep 21, 2007
Love previously served as chief operating officer of the Translational Genomics Research Institute in Phoenix and was a director of ILEX Oncology, a cancer drug development company that was acquired by Genzyme Corp.. ImaRx also named Garen Manvelian as Chief Medical Officer and promoted Jennifer Marshall to vice president of corporate development. (AZCentral -- Business)
Scientific vision Sep 18, 2007
His investment and development fingerprints are all over some of the region's most successful biotech companies: , the former Ilex Oncology Inc. and Austin's Emergent Technologies Inc.. The ties are familial, too. (San Antonio Business Journal, TX)
Cell Therapeutics, Inc. (CTI) Announces Agreement to Acquire SMi; Gains Global Rights to Brostallicin, in a New Class of Cancer Killing Agents Jul 25, 2007
Richard L. Love, a founder of SMi and former founder and CEO of ILEX Oncology, is expected to join CTI's Board of Directors ... He started two biopharmaceutical companies, Triton Biosciences Inc. and ILEX Oncology, serving as CEO in both, where he led teams that were responsible for the clinical development of numerous important therapeutic products, four of which are currently used in the practice of medicine: Betaseron(R), Fludara(R), CAMPATH(R), and Clolar(TM) ... Timothy Williamson is CBO... (PR Newswire)
Genzyme: Geared for Growth Jun 12, 2007
In addition, we are encouraged by the planned expansion of Genzyme's nascent oncology platform, acquired in 2004's purchase of ILEX Oncology, and with the proposed $345 million acquisition of Bioenvision (), subject to necessary approvals, with whom ILEX co-developed leukemia drugs Clolar and Campath. We believe Genzyme shares are compelling at current levels and our 12-month target price is $80. (BusinessWeek)
Genzyme will buy its cancer drug partner May 30, 2007
To build its arsenal of cancer drugs, Genzyme sank $1 billion into buying Ilex Oncology Inc. in 2004, acquiring the leukemia drug Campath and the American rights to Clolar. It also bought the cancer-testing business of Impath Inc. for $215 million. (Boston Globe)
